Quarterly ResultAug 5, 2026, 04:20 PM
Carlsmed Q2 Revenue Jumps 57% to $18.9M; Net Loss Widens to $10.5M
AI Summary
Carlsmed, Inc. reported a significant increase in revenue for the second quarter and first half of 2026, driven by the commercial launch of its aprevo Technology Platform. Q2 2026 revenue jumped 56.7% to $18.9 million, while year-to-date revenue rose 57.4% to $35.1 million. However, the company's net loss also widened, reaching $10.5 million for Q2 and $19.2 million year-to-date, reflecting increased operating expenses. The company expects to commercially launch its corra Cervical Plating System by December 2026.
Key Highlights
- Q2 2026 revenue increased 56.7% to $18.9 million from $12.1 million in Q2 2025.
- Q2 2026 net loss widened to $10.5 million compared to $6.8 million in Q2 2025.
- Year-to-date revenue grew 57.4% to $35.1 million from $22.3 million in 2025.
- Year-to-date net loss increased to $19.2 million from $12.5 million in 2025.
- Cash, cash equivalents, and marketable securities totaled $89.3 million as of June 30, 2026.
- Accumulated deficit reached $120.0 million as of June 30, 2026.
- Commercial launch of the corra Cervical Plating System is expected by December 2026.
Price Impact
More from CARL